Challenges in developing personalized neoantigen cancer vaccines
PD Katsikis, KJ Ishii, C Schliehe - Nature Reviews Immunology, 2024 - nature.com
The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …
Nanoparticle-based adjuvants and delivery systems for modern vaccines
Ever since the development of the first vaccine, vaccination has had the great impact on
global health, leading to the decrease in the burden of numerous infectious diseases …
global health, leading to the decrease in the burden of numerous infectious diseases …
Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines
S Gupta, S Pellett - Toxins, 2023 - mdpi.com
Vaccines are one of the most effective strategies to prevent pathogen-induced illness in
humans. The earliest vaccines were based on live inoculations with low doses of live or …
humans. The earliest vaccines were based on live inoculations with low doses of live or …
Periodic mesoporous organosilica as a nanoadjuvant for subunit vaccines elicits potent antigen-specific germinal center responses by activating naive B cells
F Li, X Feng, J Huang, M Zhang, W Liu, X Wang… - ACS …, 2023 - ACS Publications
Infection diseases such as AIDS and COVID-19 remain challenging in regard to protective
vaccine design, while adjuvants are critical for subunit vaccines to induce strong, broad, and …
vaccine design, while adjuvants are critical for subunit vaccines to induce strong, broad, and …
From periphery to center stage: 50 years of advancements in innate immunity
S Carpenter, LAJ O'Neill - Cell, 2024 - cell.com
Over the past 50 years in the field of immunology, something of a Copernican revolution has
happened. For a long time, immunologists were mainly concerned with what is termed …
happened. For a long time, immunologists were mainly concerned with what is termed …
Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia
E Kawahara, T Shibata, T Hirai, Y Yoshioka - Frontiers in Immunology, 2023 - frontiersin.org
Introduction Respiratory syncytial virus (RSV) vaccines targeting the fusion glycoprotein (F
protein) are highly effective clinically in preventing RSV challenges. The attachment …
protein) are highly effective clinically in preventing RSV challenges. The attachment …
Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate
Diarrhea caused by Shigella has been associated with high morbidity and mortality in young
children worldwide. There are no licensed vaccines, and those clinically advanced have …
children worldwide. There are no licensed vaccines, and those clinically advanced have …
Understanding immunity to influenza: implications for future vaccine development
RA Tripp - Expert Review of Vaccines, 2023 - Taylor & Francis
Introduction Influenza virus changes its genotype through antigenic drift or shift making it
difficult to develop immunity to infection or vaccination. Zoonotic influenza A virus (IAV) …
difficult to develop immunity to infection or vaccination. Zoonotic influenza A virus (IAV) …
Vaccine Strategies to Elicit Mucosal Immunity
Y Song, F Mehl, SL Zeichner - Vaccines, 2024 - mdpi.com
Vaccines are essential tools to prevent infection and control transmission of infectious
diseases that threaten public health. Most infectious agents enter their hosts across mucosal …
diseases that threaten public health. Most infectious agents enter their hosts across mucosal …
Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach
ABSTRACT Extraintestinal pathogenic Escherichia coli (ExPEC) is a leading cause of
worldwide morbidity and mortality, the top cause of antimicrobial-resistant (AMR) infections …
worldwide morbidity and mortality, the top cause of antimicrobial-resistant (AMR) infections …